Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011:55:195-234.
doi: 10.1007/978-94-007-1217-1_8.

Animal models of airway diseases

Affiliations
Review

Animal models of airway diseases

Linda F Thompson et al. Subcell Biochem. 2011.

Abstract

Over the past 20 years, the growing awareness that purinergic signaling events literally shape the immune and inflammatory responses to infection and allergic reactions warranted the development of animal models to assess their importance in vivo in acute lung injury and chronic airway diseases. The pioneer work conducted with the adenosine deaminase (ADA)-deficient mouse provided irrefutable evidence that excess adenosine (ADO) accumulating in the lungs of asthmatic patients, constitutes a powerful mediator of disease severity. These original studies launched the development of murine strains for the two major ectonucleotidases responsible for the generation of airway ADO from ATP release: CD39 and CD73. The dramatic acute lung injury and chronic lung complications, manifested by these knockout mice in response to allergens and endotoxin, demonstrated the critical importance of regulating the availability of ATP and ADO for their receptors. Therapeutic targets are currently evaluated using knockout mice and agonists/antagonists for each ADO receptor (A(1)R, A(2A)R, A(2B)R, and A(3)R) and the predominant ATP receptors (P2Y(2)R and P2X(7)R). This chapter provides an in-depth description of each in vivo study, and a critical view of the therapeutic potentials for the treatment of airway diseases.

PubMed Disclaimer

Figures

Fig. 8.1
Fig. 8.1
Purinergic regulation of fluid fluxes and barrier permeability in the lung. In the circulation, nucleotides regulate endothelial permeability to fluid and leukocytes by the balancing activities of ATP, ADP and ADO receptors. Whereas P2Y1R activation reduces the transmembrane electrical resistance (TER), P2Y2Rs, A2ARs and A2BRs all protect the lungs against vascular leakage. A second barrier protects the airways against excess fluid accumulation: the epithelial barrier. Alveolar cells express A1Rs and A2ARs which regulate fluid fluxes in and out of the airspace along ion gradients generated by the CFTR chloride (Cl) channel and the ENaC sodium (Na+) channel. During viral infection, pulmonary edema is caused by the production, release and conversion of UTP into UDP, which activates P2Y6Rs to inhibit Na+ and fluid absorption via ENaC
Fig. 8.2
Fig. 8.2
Summary of the adenosine-mediated responses in murine models of acute lung injury and chronic lung disease. The blue boxes indicate anti-inflammatory and protective effects, the green boxes indicate pro-inflammatory and damaging responses

Similar articles

Cited by

References

    1. Lucas R, Verin AD, Black SM, Catravas JD. Regulators of endothelial and epithelial barrier integrity and function in acute lung injury. Biochem Pharmacol. 2009;77:1763–1772. - PMC - PubMed
    1. Colgan SP, Eltzschig HK, Eckle T, Thompson LF. Physiological roles for ecto-5'-nucleotidase (CD73) Purinergic Signal. 2006;2:351–360. - PMC - PubMed
    1. Balestrieri ML, Malik KU, Balestrieri C, Lee TC. Types of purinoceptors and phospholipase A2 involved in the activation of the platelet-activating factor-dependent transacetylase activity and arachidonate release by ATP in endothelial cells. Prostaglandins Other Lipid Mediat. 1998;56:363–375. - PubMed
    1. Kolosova IA, Mirzapoiazova T, Adyshev D, Usatyuk P, Romer LH, Jacobson JR, Natarajan V, Pearse DB, Garcia JGN, Verin AD. Signaling pathways involved in adenosine triphosphate-induced endothelial cell barrier enhancement. Circ Res. 2005;97:115–124. - PubMed
    1. Gunduz D, Hirche F, Hartel FV, Rodewald CW, Schafer M, Pfitzer G, Piper HM, Noll T. ATP antagonism of thrombin-induced endothelial barrier permeability. Cardiovasc Res. 2003;59:470–478. - PubMed